Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Use of a Single CAR T Cell and Several Bispecific Adapters Facilitates Eradication of Multiple Antigenically Different Solid Tumors.

Lee YG, Marks I, Srinivasarao M, Kanduluru AK, Mahalingam SM, Liu X, Chu H, Low PS.

Cancer Res. 2019 Jan 15;79(2):387-396. doi: 10.1158/0008-5472.CAN-18-1834. Epub 2018 Nov 27.

PMID:
30482775
2.

The Emergence of Universal Immune Receptor T Cell Therapy for Cancer.

Minutolo NG, Hollander EE, Powell DJ Jr.

Front Oncol. 2019 Mar 26;9:176. doi: 10.3389/fonc.2019.00176. eCollection 2019. Review.

3.

Preclinical Evaluation of Bispecific Adaptor Molecule Controlled Folate Receptor CAR-T Cell Therapy With Special Focus on Pediatric Malignancies.

Lu YJ, Chu H, Wheeler LW, Nelson M, Westrick E, Matthaei JF, Cardle II, Johnson A, Gustafson J, Parker N, Vetzel M, Xu LC, Wang EZ, Jensen MC, Klein PJ, Low PS, Leamon CP.

Front Oncol. 2019 Mar 19;9:151. doi: 10.3389/fonc.2019.00151. eCollection 2019.

4.

Chimeric antigen receptor-engineered T-cell therapy for liver cancer.

Chen Y, E CY, Gong ZW, Liu S, Wang ZX, Yang YS, Zhang XW.

Hepatobiliary Pancreat Dis Int. 2018 Aug;17(4):301-309. doi: 10.1016/j.hbpd.2018.05.005. Epub 2018 May 24. Review.

PMID:
29861325
5.

Expanding the Therapeutic Window for CAR T Cell Therapy in Solid Tumors: The Knowns and Unknowns of CAR T Cell Biology.

Watanabe K, Kuramitsu S, Posey AD Jr, June CH.

Front Immunol. 2018 Oct 26;9:2486. doi: 10.3389/fimmu.2018.02486. eCollection 2018. Review.

6.

Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors.

Smith TT, Moffett HF, Stephan SB, Opel CF, Dumigan AG, Jiang X, Pillarisetty VG, Pillai SPS, Wittrup KD, Stephan MT.

J Clin Invest. 2017 Jun 1;127(6):2176-2191. doi: 10.1172/JCI87624. Epub 2017 Apr 24.

7.

Chimeric Antigen Receptor T Cells: Extending Translation from Liquid to Solid Tumors.

Morgan MA, Schambach A.

Hum Gene Ther. 2018 Oct;29(10):1083-1097. doi: 10.1089/hum.2017.251. Epub 2018 Aug 29.

PMID:
30156435
8.

IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo.

Koneru M, Purdon TJ, Spriggs D, Koneru S, Brentjens RJ.

Oncoimmunology. 2015 Jan 23;4(3):e994446. eCollection 2015 Mar.

9.

A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors.

Liu X, Ranganathan R, Jiang S, Fang C, Sun J, Kim S, Newick K, Lo A, June CH, Zhao Y, Moon EK.

Cancer Res. 2016 Mar 15;76(6):1578-90. doi: 10.1158/0008-5472.CAN-15-2524.

10.

Emerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cells.

Yazdanifar M, Zhou R, Mukherjee P.

Curr Trends Immunol. 2016;17:95-115.

11.

CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.

Martinez M, Moon EK.

Front Immunol. 2019 Feb 5;10:128. doi: 10.3389/fimmu.2019.00128. eCollection 2019. Review.

12.

Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity.

Liu L, Patel B, Ghanem MH, Bundoc V, Zheng Z, Morgan RA, Rosenberg SA, Dey B, Berger EA.

J Virol. 2015 Jul;89(13):6685-94. doi: 10.1128/JVI.00474-15. Epub 2015 Apr 15.

13.

Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.

Hillerdal V, Essand M.

BioDrugs. 2015 Apr;29(2):75-89. doi: 10.1007/s40259-015-0122-9. Review.

14.

Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.

Aldoss I, Bargou RC, Nagorsen D, Friberg GR, Baeuerle PA, Forman SJ.

Leukemia. 2017 Apr;31(4):777-787. doi: 10.1038/leu.2016.391. Epub 2016 Dec 28. Review.

PMID:
28028314
15.

Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape.

Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, Navai SA, Wakefield A, Fousek K, Bielamowicz K, Chow KK, Brawley VS, Byrd TT, Krebs S, Gottschalk S, Wels WS, Baker ML, Dotti G, Mamonkin M, Brenner MK, Orange JS, Ahmed N.

J Clin Invest. 2016 Aug 1;126(8):3036-52. doi: 10.1172/JCI83416. Epub 2016 Jul 18.

16.

Chimeric antigen receptor-T cell therapy for solid tumors require new clinical regimens.

Xu J, Tian K, Zhang H, Li L, Liu H, Liu J, Zhang Q, Zheng J.

Expert Rev Anticancer Ther. 2017 Dec;17(12):1099-1106. doi: 10.1080/14737140.2017.1395285. Epub 2017 Oct 26. Review.

PMID:
29048935
17.

CAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma: From bench to bedside.

Zhang Q, Zhang Z, Peng M, Fu S, Xue Z, Zhang R.

Oncoimmunology. 2016 Oct 28;5(12):e1251539. doi: 10.1080/2162402X.2016.1251539. eCollection 2016. Review.

18.

NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors.

Spear P, Barber A, Rynda-Apple A, Sentman CL.

Immunol Cell Biol. 2013 Jul;91(6):435-40. doi: 10.1038/icb.2013.17. Epub 2013 Apr 30.

19.

Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.

Kato D, Yaguchi T, Iwata T, Morii K, Nakagawa T, Nishimura R, Kawakami Y.

Nihon Rinsho Meneki Gakkai Kaishi. 2017;40(1):68-77. doi: 10.2177/jsci.40.68. Review.

20.

Targeting Alpha-Fetoprotein (AFP)-MHC Complex with CAR T-Cell Therapy for Liver Cancer.

Liu H, Xu Y, Xiang J, Long L, Green S, Yang Z, Zimdahl B, Lu J, Cheng N, Horan LH, Liu B, Yan S, Wang P, Diaz J, Jin L, Nakano Y, Morales JF, Zhang P, Liu LX, Staley BK, Priceman SJ, Brown CE, Forman SJ, Chan VW, Liu C.

Clin Cancer Res. 2017 Jan 15;23(2):478-488. doi: 10.1158/1078-0432.CCR-16-1203. Epub 2016 Aug 17.

Supplemental Content

Support Center